. 2014 Mar 5;54(4):1050–1060. doi: 10.1021/ci500004h

Table 1. Comparison of the Experimental pK_i and the Predicted pK_d Values for the FDA-Approved AD Drugs.

drug	target	experimental K_i (nM)	experimental (−pK_i)	HTDocking score predicted (−pK_d)
tacrine	acetylcholinesterase	225^a	6.65	6.11
galantamine	acetylcholinesterase	62^b	7.21	7.18
rivastigmine	acetylcholinesterase	920^c	6.04	6.08
donepezil	acetylcholinesterase	23^d	7.64	7.25
	glutamate [NMDA] receptor subunit 3a	700^e	6.15	7.17
	glutamate [NMDA] receptor subunit 3b	540^f	6.27	6.33
memantine	glutamate [NMDA] receptor subunit zeta-1	1200^g	5.92	6.82
	glutamate [NMDA] receptor subunit epsilon 2	1020^h	6.00	6.33

Experimental data from ref (66).

Experimental data from ref (67).

Experimental data from ref (68).

Experimental data from ref (69).

Experimental data from ref (70).

Experimental data from ref (71).

Experimental data from ref (72).

Experimental data from ref (73).

Table 1. Comparison of the Experimental pKi and the Predicted pKd Values for the FDA-Approved AD Drugs.